Oncology
Pacylex Pharmaceuticals Showcases Promising NMT Inhibitors at BIO Annual Meeting
Pacylex Pharmaceuticals Inc. highlights its innovative N-myristoyltransferase inhibitors (NMTis) at the BIO International Convention, showcasing potential breakthroughs in cancer treatment through oral zelenirstat and ADC payloads.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Bolstering Oncology Portfolio
OncoX BioPharma Inc., an affiliate of ABVC BioPharma, has acquired the Lycopenoid Lycogen® platform, a move that could generate significant revenue through a scalable royalty strategy and strengthen ABVC's position in botanical oncology innovation.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit
CNS Pharmaceuticals Inc. will present promising data on its brain-penetrating taxane candidate, TPI 287, at the upcoming Brain Tumor Biotech Summit, highlighting potential breakthroughs in treating glioblastoma and other CNS tumors.
Kairos Pharma Ltd. Showcases Promising Preclinical Results for KROS101 at ASCO 2025
Kairos Pharma Ltd. reveals preclinical data at ASCO 2025 indicating KROS101's potential to enhance cancer immunotherapy by improving T cell activity and reducing immune suppression.
Soligenix Inc. (SNGX) Reports Promising HyBryte Results for CTCL Treatment
Interim data from a Soligenix Inc. study highlights HyBryte's potential as a safer, faster-acting treatment for cutaneous T-cell lymphoma, offering new hope for patients with this chronic condition.
Lantern Pharma Shows Promise in Pediatric Brain Cancer Treatment
Lantern Pharma's experimental drug LP-184 demonstrates significant potential in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer, with preclinical studies showing remarkable improvements in survival rates.
RNAi Pioneer Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has added renowned RNA biology expert Dr. Phillip D. Zamore to its Scientific Advisory Board, potentially strengthening the company's RNA-targeted cancer therapy research and development strategy.
RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics strengthens its scientific leadership by appointing renowned RNA interference expert Dr. Phillip Zamore to its Scientific Advisory Board, potentially boosting the company's cancer therapeutic research capabilities.
Soligenix's HyBryte Shows Promising Results in Rare Cancer Treatment
Soligenix reports significant progress in treating cutaneous T-cell lymphoma (CTCL) with its experimental therapy HyBryte, demonstrating 75% treatment success after 18 weeks of clinical trials. The breakthrough offers potential hope for patients with this challenging rare skin cancer.
Calidi Biotherapeutics Unveils Promising Cancer Therapy Platform RTNova
Calidi Biotherapeutics has developed RTNova, an innovative gene therapy platform targeting tumors with minimal damage to healthy tissues, potentially revolutionizing cancer treatment approaches.
Soligenix Advances Phase 3 Trial for Cutaneous T-Cell Lymphoma Treatment, Zacks Report Shows Promise
Soligenix continues enrollment in its Phase 3 HyBryte trial for cutaneous T-cell lymphoma, with Zacks Research highlighting the trial's high potential for success and anticipated topline results in 2026.
Calidi Biotherapeutics Advances Cancer Immunotherapy Platform, Reduces Quarterly Losses
Calidi Biotherapeutics has made significant progress in its oncology research, receiving FDA clearance for a stem cell-based immunotherapy and presenting promising data on its Redtail virotherapy platform while simultaneously reducing operational expenses.
Calidi Biotherapeutics Unveils Promising Cancer Treatment Platform with Broad Therapeutic Potential
Calidi Biotherapeutics has demonstrated preclinical success with its RTNova platform, showing the ability to deliver gene-therapy payloads and kill over 60 tumor cell lines, potentially transforming cancer treatment approaches.
TransCode Therapeutics Advances RNA Cancer Therapy, Reaches Milestone in Phase 1a Trial
TransCode Therapeutics has successfully dosed 15 patients in its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138, with early data showing promising target engagement and no significant toxicities.
Kairos Pharma to Showcase Oncology Research at D. Boral Capital Global Conference
Kairos Pharma will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its innovative cancer therapeutic research, focusing on overcoming drug resistance with its lead candidate ENV105.
Soligenix's HyBryte Shows Promising Results in CTCL Treatment, Offering New Hope for Rare Skin Cancer Patients
Biotechnology company Soligenix has reported impressive interim results for HyBryte, a novel topical treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 75% response rate and potential to address a significant unmet medical need.
GeoVax Advances COVID-19, Cancer, and Biosecurity Vaccine Platforms Despite BARDA Contract Setback
GeoVax Labs reports significant progress across multiple vaccine development programs, including a multi-antigen COVID-19 vaccine for immunocompromised patients, an oncology treatment for head and neck cancer, and a Mpox/smallpox vaccine addressing global biosecurity needs.
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte™ Therapy
Soligenix's HyBryte™ therapy shows promise in treating early-stage cutaneous T-cell lymphoma, potentially addressing a significant gap in rare disease treatments within a rapidly growing global market.
TransCode Therapeutics Advances RNA Cancer Therapy in Phase 1a Trial, Shows Promising Early Results
TransCode Therapeutics reports encouraging progress in its Phase 1a trial of TTX-MC138, an RNA-based cancer therapy targeting microRNA-10b, with initial data suggesting potential effectiveness in treating metastatic tumors.
Calidi Biotherapeutics Advances Cancer Treatment with Innovative Gene Therapy Platform
Calidi Biotherapeutics has revealed promising preclinical results for its RTNova platform, offering a potential breakthrough in targeted gene therapy for cancer treatment amid rising global cancer rates.
AI Breakthrough: Predicting Brain Tumor Recurrence in Children
Researchers have developed an artificial intelligence model that can predict the likelihood of brain cancer recurrence in children using temporal learning and MRI images, potentially enabling earlier intervention and improved treatment outcomes.
Soligenix Advances HyBryte Therapy for Cutaneous T-Cell Lymphoma Treatment
Soligenix is progressing its phase 3 clinical trial for HyBryte, a novel photodynamic therapy targeting early-stage cutaneous T-cell lymphoma, with potential to provide a noninvasive and precise treatment option for patients.
GeoVax Presents Promising Clinical Data for Gedeptin® Gene Therapy in Head and Neck Cancer Treatment
GeoVax Labs revealed clinical trial results for Gedeptin®, a novel gene-directed prodrug therapy showing potential in treating advanced head and neck cancers with minimal side effects and stability in patient outcomes.
Soligenix Advances Promising Skin Cancer Treatment with 75% Response Rate
Soligenix's HyBryte™ therapy shows significant potential in treating cutaneous T-cell lymphoma, with a 75% response rate in a federally supported clinical trial. The innovative, light-activated treatment could offer new hope for patients with this rare form of skin cancer.
Kairos Pharma Receives DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma secures a Department of Defense grant to support its innovative cancer research, focusing on developing ENV105, a potential breakthrough in addressing drug resistance in prostate and lung cancers.
Soligenix's HyBryte™ Demonstrates Promising Results in Rare Skin Cancer Treatment
A novel skin cancer therapy shows a 75% response rate in treating cutaneous T-cell lymphoma, offering potential hope for patients with limited treatment options. The treatment's safety profile and rapid results could significantly impact rare cancer care.
Kairos Pharma Secures Department of Defense Grant for Lung Cancer Biomarker Research
Kairos Pharma has received a Department of Defense grant to advance research on lung cancer biomarkers, furthering its innovative approach to targeting drug resistance in cancer treatments. The company is progressing clinical trials for its lead candidates ENV105 and KROS101 with promising potential in oncology.
Ohio State Researchers Uncover Potential Breakthrough in Glioblastoma Treatment
Scientists have identified a key enzyme, PGM3, that could be crucial in developing more effective treatments for glioblastoma, one of the deadliest forms of brain cancer by targeting a critical growth pathway.